KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization - Total (2018 - 2023)

Historic Depreciation & Amortization - Total for TherapeuticsMD (TXMD) over the last 7 years, with Q4 2023 value amounting to -$185000.0.

  • TherapeuticsMD's Depreciation & Amortization - Total rose 3485.92% to -$185000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$185000.0, marking a year-over-year decrease of 1860000.0%. This contributed to the annual value of $100000.0 for FY2023, which is 8333.33% down from last year.
  • As of Q4 2023, TherapeuticsMD's Depreciation & Amortization - Total stood at -$185000.0, which was up 3485.92% from $130000.0 recorded in Q3 2023.
  • In the past 5 years, TherapeuticsMD's Depreciation & Amortization - Total registered a high of $329000.0 during Q1 2022, and its lowest value of -$284000.0 during Q4 2022.
  • Moreover, its 3-year median value for Depreciation & Amortization - Total was $128000.0 (2023), whereas its average is $85172.9.
  • Its Depreciation & Amortization - Total has fluctuated over the past 5 years, first surged by 6321.95% in 2019, then tumbled by 9179.33% in 2023.
  • TherapeuticsMD's Depreciation & Amortization - Total (Quarter) stood at $66556.0 in 2019, then tumbled by 526.71% to -$284000.0 in 2022, then skyrocketed by 34.86% to -$185000.0 in 2023.
  • Its Depreciation & Amortization - Total was -$185000.0 in Q4 2023, compared to $130000.0 in Q3 2023 and $128000.0 in Q2 2023.